gene_symbol
UNKNOWN
binding_type
antigen recognition
cytotoxicity
YES
cytotoxicity_type
DIRECT
cytotoxicity_mechanism
Infused TILs use native TCRs to recognize tumor-derived peptide–HLA class I complexes on tumor cells and kill them via perforin/granzyme release and death-receptor pathways (e.g., Fas/FasL).
enzyme_product
Off
epitope
On
variant
On
isoform
Off
hla_specific
On
gated
Off
other_modifier
Recognized primarily by CD8+ TILs; HLA-A/B/C restricted; peptides include private neoantigens and shared TAAs
trial_id_tar_ref
drug_id_tar_ref
disease_id_tar_ref
nct_id_tar_ref
NCT05868915
disease_id_num_tar_ref
1375
drug_id_num_tar_ref
3726